Embecta rises after agreeing to buy UK device maker Owen Mumford

Shares of medical device maker Embecta EMBC.O rise 2% to $8.99 premarket

Co says it will buy privately held Owen Mumford in a deal worth up to 150 million pounds ($199.10 million), expanding into drug‑delivery devices beyond diabetes

Co will pay 100 million pounds in cash upfront, with up to 50 million pounds tied to sales of Owen Mumford's Aidaptus auto-injector platform over three years - EMBC

Owen Mumford makes auto-injectors and self-injection devices used to deliver drugs for conditions such as obesity, autoimmune diseases and allergies, co says

Says the deal will help diversify revenue and support growth using its global sales network

Transaction is expected to close in fiscal Q3 2026, subject to regulatory approvals; deal funded through borrowings - EMBC

Shares down ~42% in 2025

($1 = 0.7534 pounds)